| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41440-019-0243-5 |
| P698 | PubMed publication ID | 30842612 |
| P2093 | author name string | Marcelo F Montenegro | |
| Heloisa Bettiol | |||
| Viviane C Cardoso | |||
| Marco Antonio Barbieri | |||
| Ricardo C Cavalli | |||
| Mayara Caldeira-Dias | |||
| Valéria C Sandrim | |||
| P2860 | cites work | Vitamin C supplementation in pregnancy | Q24186955 |
| Vitamin E supplementation in pregnancy | Q24187298 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays | Q25939005 | ||
| Resveratrol and Cardiovascular Diseases | Q26752801 | ||
| Diabetic complications in pregnancy: is resveratrol a solution? | Q27012844 | ||
| Resveratrol and diabetes: from animal to human studies | Q27014951 | ||
| Resveratrol and cancer: Challenges for clinical translation | Q27015712 | ||
| Nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia | Q28083676 | ||
| In Preeclampsia, the Circulating Factors Capable of Altering In Vitro Endothelial Function Precede Clinical Disease | Q58035998 | ||
| Inhibition of Lectin-Like Oxidized Low-Density Lipoprotein-1 Receptor Protects Against Plasma-Mediated Vascular Dysfunction Associated With Pre-Eclampsia | Q59546032 | ||
| Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia | Q81508545 | ||
| First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia | Q81931104 | ||
| Evaluation of oxidative stress markers in first trimester for assessment of preeclampsia risk | Q83462634 | ||
| Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats | Q84271272 | ||
| Development of an improved reverse-phase high-performance liquid chromatography method for the simultaneous analyses of trans-/cis-resveratrol, quercetin, and emodin in commercial resveratrol supplements | Q88012446 | ||
| Preeclamptic plasma stimulates the expression of miRNAs, leading to a decrease in endothelin-1 production in endothelial cells | Q88412919 | ||
| Beneficial and cautionary outcomes of resveratrol supplementation in pregnant nonhuman primates | Q33613239 | ||
| Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment. | Q33687481 | ||
| A protocol to identify non-classical risk factors for preterm births: the Brazilian Ribeirão Preto and São Luís prenatal cohort (BRISA). | Q34581586 | ||
| Arginase contributes to endothelial cell oxidative stress in response to plasma from women with preeclampsia | Q34997667 | ||
| First-Trimester Maternal Serum Levels of sFLT1, PGF and ADMA Predict Preeclampsia | Q35532857 | ||
| Trans-, cis-, and dihydro-resveratrol: a comparative study. | Q35856568 | ||
| Regulatory Cytokine Expression and Preterm Birth: Case-Control Study Nested in a Cohort | Q36093699 | ||
| Therapeutically targeting mitochondrial redox signalling alleviates endothelial dysfunction in preeclampsia | Q37239844 | ||
| Heme oxygenase in pregnancy and preeclampsia | Q37312044 | ||
| The global impact of pre-eclampsia and eclampsia | Q37493240 | ||
| The role of nitric oxide synthase inhibition by asymmetric dimethylarginine in the pathophysiology of preeclampsia | Q37614802 | ||
| Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. | Q37844756 | ||
| A possible protective role of Nrf2 in preeclampsia | Q38222393 | ||
| Resveratrol and endothelial nitric oxide. | Q38258814 | ||
| Resveratrol: anti-obesity mechanisms of action. | Q38269066 | ||
| The role of arginine, homoarginine and nitric oxide in pregnancy | Q38532645 | ||
| Resveratrol protects from lipopolysaccharide-induced inflammation in the uterus and prevents experimental preterm birth. | Q38623566 | ||
| Preeclamptic plasma induces transcription modifications involving the AP-1 transcriptional regulator JDP2 in endothelial cells | Q39080368 | ||
| Comparison of PrestoBlue and MTT assays of cellular viability in the assessment of anti-proliferative effects of plant extracts on human endothelial cells | Q39084515 | ||
| Oxidative stress in pre-eclampsia; have we been looking in the wrong place? | Q39304239 | ||
| Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension | Q39855290 | ||
| Myeloperoxidase is not a good biomarker for preeclampsia prediction. | Q41580008 | ||
| Plasma from pre-eclamptic patients induces the expression of the anti-angiogenic miR-195-5p in endothelial cells. | Q41834849 | ||
| Efficacy of resveratrol to supplement oral nifedipine treatment in pregnancy-induced preeclampsia | Q42269581 | ||
| Effects of resveratrol on NO secretion stimulated by insulin and its dependence on SIRT1 in high glucose cultured endothelial cells | Q42478626 | ||
| Up-regulation of endothelial nitric oxide synthase (eNOS), silent mating type information regulation 2 homologue 1 (SIRT1) and autophagy-related genes by repeated treatments with resveratrol in human umbilical vein endothelial cells | Q42710775 | ||
| Hemodynamic effects of inducible nitric oxide synthase inhibition combined with sildenafil during acute pulmonary embolism | Q42922060 | ||
| Role of nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia | Q43057030 | ||
| Serum from healthy pregnant women reduces oxidative stress in human umbilical vein endothelial cells | Q44048789 | ||
| Role of resveratrol in regulation of cellular defense systems against oxidative stress. | Q46250411 | ||
| Management of preeclampsia | Q46312131 | ||
| The NOX2-derived reactive oxygen species damaged endothelial nitric oxide system via suppressed BKCa/SKCa in preeclampsia | Q46433838 | ||
| Resveratrol mitigates trophoblast and endothelial dysfunction partly via activation of nuclear factor erythroid 2-related factor-2. | Q50060538 | ||
| Epigallocatechin gallate enhances treatment efficacy of oral nifedipine against pregnancy-induced severe pre-eclampsia: A double-blind, randomized and placebo-controlled clinical study | Q50196685 | ||
| Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. | Q51037240 | ||
| Prediction of first-trimester preeclampsia: Relevance of the oxidative stress marker MDA in a combination model with PP-13, PAPP-A and beta-HCG. | Q52671279 | ||
| Increased oxidative stress from early pregnancy in women who develop preeclampsia. | Q53196491 | ||
| Resveratrol Protects Against Pathological Preterm Birth by Suppression of Macrophage-Mediated Inflammation. | Q53480409 | ||
| Difference of endothelial function during pregnancies as a method to predict preeclampsia. | Q53727721 | ||
| Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion. | Q53790457 | ||
| NO in Early Pregnancy and Development of Preeclampsia | Q56794529 | ||
| EndothelialFOSexpression and pre-eclampsia | Q56970549 | ||
| P433 | issue | 8 | |
| P921 | main subject | pre-eclampsia | Q61335 |
| P304 | page(s) | 1166-1174 | |
| P577 | publication date | 2019-03-06 | |
| P1433 | published in | Hypertension Research | Q15762136 |
| P1476 | title | Resveratrol improves endothelial cell markers impaired by plasma incubation from women who subsequently develop preeclampsia | |
| P478 | volume | 42 |
Search more.